172 related articles for article (PubMed ID: 37636008)
1. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
4. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
[TBL] [Abstract][Full Text] [Related]
5. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Pintar Š; Hanžel J; Drobne D; Koželj M; Kurent T; Smrekar N; Novak G
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399583
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
Kobayashi T; Ito H; Ashida T; Yokoyama T; Nagahori M; Inaba T; Shikamura M; Yamaguchi T; Hori T; Pinton P; Watanabe M; Hibi T
Intest Res; 2021 Oct; 19(4):448-460. PubMed ID: 32806876
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
8. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
10. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
11. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
12. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review.
Patel D; Martin S; Luo M; Ursos L; Lirio RA; Kamble P; Wang S
Crohns Colitis 360; 2022 Jul; 4(3):otac020. PubMed ID: 36777427
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Bergqvist V; Holmgren J; Klintman D; Marsal J
Aliment Pharmacol Ther; 2022 Jun; 55(11):1389-1401. PubMed ID: 35470449
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.
Hu Q; Tang XZ; Liu F; Liu DW; Cao B
Therap Adv Gastroenterol; 2023; 16():17562848231166227. PubMed ID: 37124368
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease: 2 Randomized Phase 3 Trials.
Hanauer SB; Sands BE; Schreiber S; Danese S; Kłopocka M; Kierkuś J; Kulynych R; Gonciarz M; Sołtysiak A; Smoliński P; Srećković S; Valuyskikh E; Lahat A; Horyński M; Gasbarrini A; Osipenko M; Borzan V; Kowalski M; Saenko D; Sardinov R; Lee SJ; Kim S; Bae Y; Lee S; Lee S; Lee JH; Yang S; Lee J; Lee J; Kim JM; Park G; Sandborn WJ; Colombel JF
Gastroenterology; 2024 May; ():. PubMed ID: 38788861
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
